ATG-037-001
29 Nov 2022
Trial Summary
This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Acronym:
ATG-037-001
ACTRN/NCT /ethics:
NCT05205109
Scientific title:
A Phase I, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Sponsor / Cooperative group:
Antengene Therapeutics Limited
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 Years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2022-12-31 |
| Anticipated End Date | 2024-08-30 |
Participating Hospitals
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.ORiley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |